Advisors Asset Management’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$497K Sell
6,353
-11,513
-64% -$785K 0.01% 988
2026
Q1
$1.15M Sell
17,866
-1,247
-7% -$87.9K 0.02% 757
2025
Q4
$1.29M Sell
19,113
-3,549
-16% -$239K 0.02% 724
2025
Q3
$1.66M Sell
22,662
-891
-4% -$59.2K 0.03% 645
2025
Q2
$1.23M Sell
23,553
-2,191
-9% -$125K 0.02% 714
2025
Q1
$1.64M Sell
25,744
-44
-0.2% -$2.56K 0.03% 610
2024
Q4
$1.23M Sell
25,788
-13,858
-35% -$711K 0.02% 691
2024
Q3
$2.27M Buy
39,646
+2,174
+6% +$125K 0.04% 528
2024
Q2
$1.96M Sell
37,472
-5,587
-13% -$245K 0.04% 548
2024
Q1
$1.75M Buy
43,059
+2,505
+6% +$93.9K 0.03% 591
2023
Q4
$1.5M Sell
40,554
-5,044
-11% -$190K 0.03% 611
2023
Q3
$1.74M Buy
45,598
+287
+0.6% +$11.8K 0.04% 552
2023
Q2
$1.63M Sell
45,311
-285
-0.6% -$9.72K 0.03% 579
2023
Q1
$1.74M Buy
45,596
+1,732
+4% +$81.2K 0.04% 557
2022
Q4
$2.5M Buy
43,864
+8,352
+24% +$428K 0.05% 441
2022
Q3
$1.4M Buy
35,512
+742
+2% +$32.8K 0.03% 604
2022
Q2
$1.53M Buy
34,770
+7,331
+27% +$317K 0.03% 608
2022
Q1
$1.09M Sell
27,439
-539
-2% -$19.2K 0.02% 779
2021
Q4
$1.12M Buy
27,978
+1,486
+6% +$55.5K 0.02% 802
2021
Q3
$1.08M Buy
26,492
+1,661
+7% +$69.4K 0.02% 790
2021
Q2
$1.13M Buy
24,831
+3,471
+16% +$154K 0.02% 799
2021
Q1
$890K Buy
21,360
+4,127
+24% +$188K 0.01% 851
2020
Q4
$736K Buy
17,233
+9,488
+123% +$341K 0.01% 861
2020
Q3
$204K Buy
7,745
+3,588
+86% +$99.9K ﹤0.01% 1179
2020
Q2
$111K Buy
+4,157
New +$93.8K ﹤0.01% 1279

Other funds holding HALO

Advisors Asset Management's HALO Position: Q2 2026 in Review

Advisors Asset Management reduced its Halozyme (HALO) stake by 64% in Q2 2026, selling an estimated $785K and leaving 6,353 shares worth $497K. The position accounts for 0.01% of the portfolio, ranked #988.

Advisors Asset Management first reported a position in HALO in Q2 2020 and has held it in 25 quarters since. The position peaked at $2.5M in Q4 2022. 668 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Advisors Asset Management held 6,353 shares of Halozyme worth $497K as of Q2 2026.
  • Advisors Asset Management sold 11,513 Halozyme shares in Q2 2026, an estimated $785K.
  • Halozyme made up 0.01% of Advisors Asset Management's portfolio in Q2 2026, its #988 holding.
  • Advisors Asset Management first reported a position in Halozyme in Q2 2020 and has held it in 25 quarters since.
  • Advisors Asset Management's Halozyme position peaked at $2.5M in Q4 2022.
  • 668 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Advisors Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.